These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 1301361)

  • 1. Pharmacokinetics of nefazodone following multiple escalating oral doses in the dog.
    Shukla UA; Kaul S; Marathe PH; Pittman KA; Barbhaiya RH
    Eur J Drug Metab Pharmacokinet; 1992; 17(4):309-18. PubMed ID: 1301361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of nefazodone in the dog following single oral administration.
    Shukla UA; Marathe PH; Labudde JA; Pittman KA; Barbhaiya RH
    Eur J Drug Metab Pharmacokinet; 1992; 17(4):301-8. PubMed ID: 1301360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Steady-state pharmacokinetics of nefazodone in subjects with normal and impaired renal function.
    Barbhaiya RH; Brady ME; Shukla UA; Greene DS
    Eur J Clin Pharmacol; 1995; 49(3):229-35. PubMed ID: 8666000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the steady-state pharmacokinetics of nefazodone after administration of 200 mg twice daily or 400 mg once daily in the morning or evening.
    Marathe PH; Lee JS; Greene DS; Barbhaiya RH
    Br J Clin Pharmacol; 1996 Jan; 41(1):21-7. PubMed ID: 8824689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonlinear pharmacokinetics of nefazodone after escalating single and multiple oral doses.
    Kaul S; Shukla UA; Barbhaiya RH
    J Clin Pharmacol; 1995 Aug; 35(8):830-9. PubMed ID: 8522641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nefazodone pharmacokinetics: assessment of nonlinearity, intra-subject variability and time to attain steady-state plasma concentrations after dose escalation and de-escalation.
    Barbhaiya RH; Shukla UA; Chaikin P; Greene DS; Marathe PH
    Eur J Clin Pharmacol; 1996; 50(1-2):101-7. PubMed ID: 8739819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single and multiple dose pharmacokinetics of nefazodone in subjects classified as extensive and poor metabolizers of dextromethorphan.
    Barbhaiya RH; Buch AB; Greene DS
    Br J Clin Pharmacol; 1996 Nov; 42(5):573-81. PubMed ID: 8951188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A study of the effect of age and gender on the pharmacokinetics of nefazodone after single and multiple doses.
    Barbhaiya RH; Buch AB; Greene DS
    J Clin Psychopharmacol; 1996 Feb; 16(1):19-25. PubMed ID: 8834414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-dose pharmacokinetics of nefazodone in healthy young and elderly subjects and in subjects with renal or hepatic impairment.
    Barbhaiya RH; Shukla UA; Greene DS
    Eur J Clin Pharmacol; 1995; 49(3):221-8. PubMed ID: 8665999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coadministration of nefazodone and benzodiazepines: III. A pharmacokinetic interaction study with alprazolam.
    Greene DS; Salazar DE; Dockens RC; Kroboth P; Barbhaiya RH
    J Clin Psychopharmacol; 1995 Dec; 15(6):399-408. PubMed ID: 8748428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics, absolute bioavailability, and disposition of [14C]nefazodone in the dog.
    Shukla UA; Marathe PH; Pittman KA; Barbhaiya RH
    Drug Metab Dispos; 1993; 21(3):502-7. PubMed ID: 8100508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety, tolerance, and preliminary pharmacokinetics of nefazodone after administration of single and multiple oral doses to healthy adult male volunteers: a double-blind, phase I study.
    Barbhaiya RH; Marathe PH; Greene DS; Mayol RF; Shukla UA; Gammans RR; Pittman KA; Robinson D
    J Clin Pharmacol; 1995 Oct; 35(10):974-84. PubMed ID: 8568015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coadministration of nefazodone and benzodiazepines: IV. A pharmacokinetic interaction study with lorazepam.
    Greene DS; Salazar DE; Dockens RC; Kroboth P; Barbhaiya RH
    J Clin Psychopharmacol; 1995 Dec; 15(6):409-16. PubMed ID: 8748429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of interaction between nefazodone and cimetidine: a steady state pharmacokinetic study in humans.
    Barbhaiya RH; Shukla UA; Greene DS
    Br J Clin Pharmacol; 1995 Aug; 40(2):161-5. PubMed ID: 8562300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics, absolute bioavailability, and disposition of [14C]nefazodone in humans.
    Barbhaiya RH; Dandekar KA; Greene DS
    Drug Metab Dispos; 1996 Jan; 24(1):91-5. PubMed ID: 8825195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coadministration of nefazodone and benzodiazepines: II. A pharmacokinetic interaction study with triazolam.
    Barbhaiya RH; Shukla UA; Kroboth PD; Greene DS
    J Clin Psychopharmacol; 1995 Oct; 15(5):320-6. PubMed ID: 8830062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single- and multiple-dose pharmacokinetics of nefazodone in patients with hepatic cirrhosis.
    Barbhaiya RH; Shukla UA; Natarajan CS; Behr DA; Greene DS; Sainati SM
    Clin Pharmacol Ther; 1995 Oct; 58(4):390-8. PubMed ID: 7586930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The lack effect of food on the bioavailability of nefazodone tablets.
    Dockens RC; Greene DS; Barbhaiya RH
    Biopharm Drug Dispos; 1996 Mar; 17(2):135-43. PubMed ID: 8907720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absorption and presystemic metabolism of nefazodone administered at different regions in the gastrointestinal tract of humans.
    Marathe PH; Salazar DE; Greene DS; Brennan J; Shukla UA; Barbhaiya RH
    Pharm Res; 1995 Nov; 12(11):1716-21. PubMed ID: 8592675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of hepatic impairment on the pharmacokinetics of nefazodone and two of its metabolites after single and multiple oral doses.
    Ferry N; Bernard N; Cuisinaud G; Rougier P; Trepo C; Sassard J
    Fundam Clin Pharmacol; 1994; 8(5):463-73. PubMed ID: 7875642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.